Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate.

[1]  R. Gold,et al.  Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate. , 2015, International journal of MS care.

[2]  M. Hutchinson,et al.  Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel. , 2014, Multiple sclerosis and related disorders.

[3]  I. Nestorov,et al.  Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers. , 2013, Clinical therapeutics.

[4]  D. Arnold,et al.  Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. , 2012, The New England journal of medicine.

[5]  David H. Miller,et al.  Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. , 2012, The New England journal of medicine.

[6]  M. Gönen,et al.  Reliability of adverse symptom event reporting by clinicians , 2012, Quality of Life Research.

[7]  W. Rief,et al.  Lessons learned from placebo groups in antidepressant trials , 2011, Philosophical Transactions of the Royal Society B: Biological Sciences.

[8]  T. Jacobson.  A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. , 2010, Mayo Clinic proceedings.

[9]  Ludwig Kappos,et al.  Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study , 2008, The Lancet.

[10]  Serguei V. S. Pakhomov,et al.  Agreement between patient-reported symptoms and their documentation in the medical record. , 2008, The American journal of managed care.

[11]  J. Paolini,et al.  Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire©: results from a randomised placebo-controlled clinical trial , 2008, International journal of clinical practice.

[12]  G. Geisslinger,et al.  PGD2 metabolism in plasma: kinetics and relationship with bioactivity on DP1 and CRTH2 receptors. , 2007, Biochemical pharmacology.

[13]  N. Santanello,et al.  Validation of a questionnaire to assess niacin-induced cutaneous flushing , 2007, Current medical research and opinion.

[14]  J. Morrow,et al.  Quantification of F2-isoprostanes as a biomarker of oxidative stress , 2007, Nature Protocols.

[15]  A. Avins,et al.  Brief Communication: Better Ways To Question Patients about Adverse Medical Events , 2006, Annals of Internal Medicine.

[16]  S. Tepper,et al.  Assessment of Adverse Events Associated With Triptans—Methods of Assessment Influence the Results , 2004, Headache.

[17]  J. Morrow,et al.  Simplification of the mass spectrometric assay for the major urinary metabolite of prostaglandin D2. , 1993, Journal of chromatography.

[18]  B. Gandevia,et al.  DECLARATION OF HELSINKI. , 1964, The Medical journal of Australia.

[19]  H. Zimmerman.  Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver , 1978 .